Tracking RTS,S, R21, and Next-Generation Malaria Vaccines
Updated July 2026. Malaria causes 610,000 deaths annually (WHO 2024 data), with about 438,000 African children under 5 dying from the disease each year. Two WHO-recommended vaccines are now in routine use: RTS,S/AS01 (Mosquirix), recommended by WHO in October 2021, and R21/Matrix-M, recommended in October 2023 and WHO-prequalified in December 2023. Both are given as a 4-dose schedule from around 5 months of age and reduce clinical malaria by more than 50% in the first year post-vaccination — rising to about 75% when used seasonally alongside seasonal malaria chemoprevention. Rollout scale (2026): More than 20 African countries have integrated malaria vaccines into routine immunization programs, and over 24 million doses have been delivered. Uganda launched Africa's largest malaria vaccination campaign in March 2025 (2.278 million R21 doses across 105 districts, targeting 1.1 million children under 2). Global annual demand is projected at 40–60 million doses by 2026 and 80–100 million doses by 2030. This tracker monitors both approved vaccines plus emerging candidates including whole sporozoite vaccines (PfSPZ), viral vector vaccines, and novel mRNA platforms.
Developer: GlaxoSmithKline (GSK) / PATH Malaria Vaccine Initiative
Platform: Recombinant protein vaccine targeting P. falciparum circumsporozoite protein (CSP) with AS01 adjuvant
Efficacy: 30-40% against clinical malaria, 30% reduction in severe malaria in children aged 5-17 months (Phase 3 trials)
Dosing: 4-dose schedule (0, 1, 2 months, plus booster at 18-20 months)
Status: Deployed in Ghana, Kenya, Malawi since 2019. Over 2 million children vaccinated. WHO recommendation October 2021. Limited by moderate efficacy and complex dosing schedule.
Key Trials: Phase 3 trial across 7 African countries (15,000+ children), demonstrated safety and moderate efficacy. Real-world implementation ongoing through WHO pilot programs.
Developer: University of Oxford / Serum Institute of India (SII)
Platform: Virus-like particle (VLP) vaccine with Matrix-M adjuvant targeting CSP
Efficacy: 77% efficacy with seasonal booster in Phase 2b trials (Burkina Faso), 68-75% over 3 years with boosters
Dosing: 3-dose primary series (0, 1, 2 months) plus seasonal boosters
Status: WHO recommendation October 2023; WHO prequalification granted December 2023. Now in routine immunization programs across more than 20 African countries. Uganda's March 2025 rollout is the largest to date — 2.278 million R21 doses distributed to 105 districts, targeting 1.1 million children under 2 (dosing at 6, 7, 8, and 18 months). Serum Institute of India has established production capacity of 100+ million doses annually. Gavi-subsidized price of approximately $0.20 per dose for eligible countries makes it the most affordable malaria vaccine to date.
Key Trials: Phase 3 trial in 4 African countries (4,800 children); long-term follow-up ongoing. Additional trials in mass vaccination campaigns including all ages (adults + children) are underway in The Gambia and Burkina Faso.
Developer: Sanaria Inc.
Platform: Whole sporozoite vaccine using radiation-attenuated live P. falciparum parasites
Efficacy: Up to 80% protection in controlled human malaria infection (CHMI) studies
Dosing: 5-dose direct venous inoculation (DVI) regimen
Status: Phase 3 trial in Equatorial Guinea and Tanzania (3,600 participants). Addresses administration challenges for field deployment. Previous CHMI studies showed high protective efficacy.
Challenge: Requires direct venous inoculation and cryopreservation, limiting field deployment feasibility.
Developer: University of Oxford
Platform: Prime-boost viral vector vaccine using chimpanzee adenovirus (ChAd63) and modified vaccinia Ankara (MVA)
Target: Multiple P. falciparum antigens including ME-TRAP
Status: Phase 2b efficacy trial in Kenya (450 participants). Aims to induce T-cell immunity complementing antibody-based vaccines.
Developer: African Malaria Network Trust (AMANET)
Platform: Blood-stage vaccine targeting GLURP and MSP3 proteins
Goal: Prevent disease rather than infection by targeting blood-stage parasites
Status: Phase 2b trial in Burkina Faso and Gabon (1,200 participants) testing in combination with seasonal malaria chemoprevention (SMC).
Developer: BioNTech
Platform: mRNA technology encoding P. falciparum circumsporozoite protein (CSP)
Status: Phase 1 trial in Germany and Gabon (120 participants). First mRNA malaria vaccine to enter clinical testing. Evaluating multiple dose levels and schedules.
Innovation: Applies proven mRNA platform from COVID-19 vaccines to malaria. Potential for rapid development and manufacturing scale-up.
Developer: Sanaria Inc.
Platform: Chemoprophylaxis vaccination using live sporozoites with antimalarial drug coverage
Status: Phase 2 trial in Tanzania (300 participants) optimizing regimens for field deployment.
Concept: Uses live parasites under drug coverage to generate immunity, showing high efficacy in controlled settings.
Developer: Seattle Children's Research Institute
Platform: Genetically attenuated parasite (GAP) with three gene deletions
Status: Phase 1 trial in USA and Tanzania (80 participants). Testing safety and protective efficacy in CHMI studies.
Innovation: Uses genetic modification instead of radiation for attenuation.
Malaria vaccine development faces unique challenges: the parasite's complex life cycle, extensive antigenic variation, and incomplete understanding of protective immunity. Current vaccines provide moderate protection requiring multiple doses and boosters. The 2023 WHO approval of R21/Matrix-M represents significant progress, but achieving high-efficacy, durable protection remains the ultimate goal. Combination approaches and next-generation platforms offer hope for breakthrough vaccines.